Flamingo Therapeutics ('Flamingo'), a company that provides RNA-targeted therapies, announced on Thursday that it has named Ezra Cohen, MD as its new director.

Dr Cohen, a medical oncologist and cancer researcher, presently serves as the chief medical officer of Oncology for Tempus AI. He has most recently served as the chief of the Division of Hematology-Oncology and the associate director of Clinical Science at UC San Diego (UCSD) Moores Cancer Center. He has also headed the Precision Immunotherapy Clinic and co-directed the San Diego Center for Precision Immunotherapy at UCSD. He has served for 15 years at the University of Chicago, where he was the co-director of the head and Neck Cancer Program and Hematology/Oncology Fellowship Program director.

Stephane van Rooijen, MD, MBA, chief executive officer of Flamingo, said, 'Ezra is a recognized leader in oncology drug development and cancer research, and we feel privileged that he will join us as we continue to advance our lead therapeutic danvatirsen in the PEMDA-HN Phase 2 trial in Head & Neck Cancer (HNSCC) and a Phase 1 investigator-initiated study in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS).'